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生検キット（Bard MONOPTY, C. R. Bard Inc., New 
Jersey, USA）を用いた32）（図１）。検体を １) ホルマ 

























































　T1強調像（ a, c : 前額断・棘上筋、b, d : 水平断・棘下筋）
　a : 中垣分類 Grade 1、b : 中垣分類 Grade 1、c : 中垣分類 Grade 1、d : 中垣分類 Grade 1
　矢印（橙）は棘上筋を示す。矢印（黄）は棘下筋を示す。
図３．MRI所見　脂肪浸潤進行例
　T1強調像（ a, c : 前額断・棘上筋、b, d : 水平断・棘下筋）






















においてGrade 0 が12肩、Grade 1 が13肩、Grade 2 が
11肩で、脂肪浸潤あり群24肩（65％）、脂肪浸潤なし群
12肩（35％）であった。棘下筋における筋線維間の脂
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The analysis of the relationship among clinical features,
MRI and pathological findings in the patients with torn
rotator cuff muscles of the shoulder
－special reference to the findings of biopsied muscular tissue samples －
Daisaku Tsuruta*, Nariyuki Mura**, Michiaki Takagi*
*Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine
**Department of Orthopaedic Surgery, Tanshinkai Yoshioka Hospital
Purpose : To clarify the pathology of the fatty degeneration on MRI in the patients with torn rotator 
cuf muscles of the shoulder, and clinical sense of this phenomenon.
Materials : Forty-one shoulders in forty-three patients with rotator cuf tears, treated surgicaly in our 
hospital.
Methods : Size of tear and fatty degeneration were evaluated on the MRI using Nakagaki’s 
classification. Needle biopsy was done at the supraspinatus and infraspinatus muscle, and the biopsy 
organization was evaluated about the fatty infiltration between muscle fibers. We evaluated and 
analyzed the relationship between the clinical, MRI and pathological findings statisticaly.
Results : There were fatty degeneration in the MRI, and fat cel infiltration between the muscle fibers. 
In the supraspinatus and infraspinatus, size of tear was large in the fatty degeneration (+) group and 
fatty infiltration (+) group. In the supraspinatus, there was a relationship between the fatty 
degeneration on MRI and fatty infiltration between muscle fibers on pathology.
Conclusion : The fatty degeneration, observed as intramuscular high signal in MRI, was refracted the 
fat cel between muscle fibers.
Key words : Rotator cuf, Fatty degeneration, Pathological findings, Fatty infiltration
ABSTRACT
intravenous versus epidural droperidol
－ 51 －
Background
　Appropriate analgesia is important for postopera-
tive pain relief, the prevention of postoperative 
nausea and vomiting (PONV) and early postoperative 
recovery1). Droperidol has strong antiemetic activity 
and is administrated for prophylaxis of PONV2). An 
intravenous route of administration is generaly 
recommended for droperidol3). The intravenous (IV) 
injection of droperidol bolus at the end of the surgery 
is recommended for prophylactic antiemetic therapy2). 
Also, the repeated IV infusion of an antiemetic mixed 
with an opioid has been performed in the setting of 
patient-controled analgesia (PCA)4), 5).
　In contrast to IV administration, the continuous 
epidural injection (CEPI) of droperidol has been used 
along with epidural block for postoperative pain relief 
in Japan6)-8). It was reported that droperidol given by 
CEPI was more efective than placebo6)-8).
　However, the advantage of the epidural injection 
(EPI) of droperidol compared with IV administration 
is not clear. Also, a comparison between EPI and IV 
injection of a droperidol bolus showed that the IV 
route was superior to the EPI route for prophylaxis of 
PONV9). We doubted the eficacy of the CEPI of 
droperidol in Japan. The continuous IV infusion 
(CIVI) of droperidol or its repeated IV infusion in the 
setting of PCA may be more efective than CEPI. 
However, this has not yet been investigated.
　We planed this study to evaluate the eficacy of the 
CEPI of droperidol. We hypothesized that the CIVI of 
A comparison of continuous intravenous infusion versus
continuous epidural infusion of droperidol for the prevension
of post operative nausea and vomiting
Masayuki Okada
Department of Anesthesiology, Faculty of Medicine, Yamagata University
（Accepted May 1, 2014）
Yamagata Med J 2014；32(2)：51-58
Background : The continuous epidural injection (CEPI) of droperidol has been used in Japan for 
prophylaxis of postoperative nausea and vomiting (PONV). To evaluate the CEPI of droperidol, we 
compared the eficacy of droperidol given by the CEPI with given by the continuous intravenous 
injection (CIVI).
Methods : The patients scheduled for gynecological surgery accompanied by epidural analgesia were 
randomly alocated to an CEPI or CIVI group. In the CEPI group, droperidol (1.25 mg) was injected 
epiduraly at the time of suturing folowed a CEPI of droperidol (5 mg in 48ml) at 1 ml/h.  In the CIVI 
group, droperidol (1.25 mg) was injected intravenously at the time of suturing folowed a CIVI of 
droperidol (5 mg in 48ml) at 1 ml/h. The incidence and severity of PONV were evaluated in both groups.
Results : 103 patients in the CEPI group and 102 patients in the CIVI group were included. The 
incidence of PONV in the first 24 hours (37.9% in the CEPI group and 32.4% in the CIVI group) and the 
severity of nausea during the first 72 hours were not diferent significantly between the two groups.
Conclusion : The eficacy of droperidol was not diferent comparing CEPI with CIVI.
Key words : postoperative nausea and vomiting (PONV), prophylaxis of PONV, droperidol, the 




droperidol would be superior to CEPI for prophylaxis 
of PONV. To test our hypothesis, we compared the 
two routes of administration in gynecologic patients, 




　This study was approved by the Ethics Committee 
of Yamagata University, and written informed 
consent was obtained from al patients. From 
September 2005 to May 2008, female patients were 
enroled at Yamagata University Hospital (Yamagata, 
Japan). The patients ranged in age from 20~69 years 
and were in the American Society of Anesthesiologists 
Physical Status (ASA-PS) category 1 or 2. Al patients 
were scheduled for elective gynecological abdominal 
surgery under general anesthesia accompanied by 
epidural analgesia. Patients were excluded based on 
the folowing criteria: impossible to communicate 
suficiently in Japanese; the use of opioids, 
antipsychotic drugs, antidepressants, adrenocorti-
costeroids, antiemetics or antihistamines; pregnancy; 
diseases of the central nervous system; or a history of 
convulsions. A 12-lead ECG was obtained in al 
patients in the month before surgery. Patients with a 
QTc >0.470 seconds or ventricular premature 
contractions >6 beats/minutes were excluded.
 
Protocol
　The patients were randomly alocated to an CEPI 
or CIVI group. The medical staf was blinded to their 
randomization assignment except for the anesthesi-
ologist in charge of the case. Anesthetic management 
was the same in each group as folows. Patients were 
premedicated oraly with ranitidine hydrochloride 
(150 mg) two hours before arrival at the operating 
room (OR). If necessary, 5~10 mg diazepam was 
added oraly one hour before arrival. On arrival at the 
OR, a 3-lead ECG, pulse oximeter and noninvasive 
blood pressure monitor (MP70; Royal Philips 
Electronics, Amsterdam, Netherlands) were attached 
to each patient. If invasive blood pressure monitoring 
was necessary, cannulation of the radial artery was 
performed after induction of general anesthesia. IV 
injection of acetated Ringer’s solution was also 
started before the induction of anesthesia. An 
epidural catheter was inserted at the interspace 
between Th9 and L2. An anesthesiologist who has 
two or more years of experience managed the 
insertion of the epidural catheter. The catheter was 
aspirated and 2 ml of 0.75% ropivacaine was injected 
into the catheter to verify appropriate placement of 
the catheter tip. If no adverse reactions occurred with 
these two tests, general anesthesia was induced with 
IV thiopental sodium (3~4 mg/kg) after inhalation of 
oxygen (O2, 5 L/min) for several minutes. When 
patients lost consciousness, inhalation of sevoflurane 
was started with an FiO2 of 100%. Vecuronium 
bromide (0.1 mg/kg) was injected intravenously, and 
tracheal intubation was performed. After tracheal 
intubation was completed, mechanical ventilation 
was started with an FiO2 of 45-60%. Anesthesia was 
maintained  using  sevoflurane  (1~3%)  and  IV 
fentanyl, and epidural block was performed with 
ropivacaine. The volume of fluid infusion was 
adjusted according to the condition of each patient. If 
necessary, a plasma expander or packed red cels were 
administered. When systolic blood pressure (SBP) 
was <80 mmHg, patients were given IV ephedrine 
hydrochloride (4~8 mg) or methoxamine hydrochlo-
ride (1 mg).  The need for these vasoconstrictors was 
based on the judgment of the anesthesiologist in 
charge. Al patients were given an epidural injection 
of morphine (2 mg) in 5 ml of saline at the beginning 
of the operation and 10 ml of 0.23% ropivacaine at the 
time of suturing of the operative wound. After the end 
of the operation, inhalation of sevoflurane was 
discontinued.  When  spontaneous  respiration 
appeared, atropine sulfate (1 mg) and neostigmine (2 
mg) were injected intravenously to reverse the efects 
of vecuronium bromide. The patients were extubated 
when they woke up and resumed spontaneous 
respiration. After extubation, the patients left the OR 
when they were stable based on the judgment of the 
anesthesiologist in charge. After leaving the OR, the 
folowing parameters were monitored: ECG, blood 
pressure, heart rate, body temperature, oxygen 
saturation (pulse oximeter), and clinical status.
　Droperidol was administered at the time of 
suturing of the operative wound. In the CEPI group, 
droperidol (1.25 mg) in 5 ml of saline was injected 
epiduraly at the time of suturing. In addition, a CEPI 
intravenous versus epidural droperidol
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of morphine (4 mg), 1% lidocaine (46 ml) and 
droperidol (5 mg in 2 ml) was started at a rate of 1 
ml/h at the time the patient left the OR. This group 
also received a CIVI of saline (48 ml) at 1 ml/h at the 
same time as the CEPI. In the CIVI group, droperidol 
(1.25 mg) in 5 ml of saline was injected intravenously 
at the time of suturing. In addition, a CEPI of 
morphine (4 mg), 1% lidocaine (46 ml) and saline (2 
ml) was started at a rate of 1 ml/h at the time the 
patient left the OR. This group also received a CIVI of 
droperidol (5 mg in 2 ml) and saline (46 ml) at 1 ml/h 
starting at the same time as the CEPI. The CEPI and 
CIVI were continued for at least 24 hours in both 
groups. A disposable infusion pump (Coopdech 
Syrinjector®, Daiken-iki, Osaka, Japan) was used for 
both the CEPI and CIVI. The contents of the 
disposable pumps could not be identified based on 
appearance. After emergence from anesthesia, the 
patients were supplemented with an intramuscular 
injection of pentazocine (15 mg) or anal administra-
tion of diclofenac sodium (25 mg) for postoperative 
pain, and IV injection of metoclopramide (10 mg) for 
severe PONV. On the first postoperative day, the 
patients started drinking water and taking oral 
loxoprofen sodium hydrate (180 mg/day) for pain 
relief.  Standing and walking were also attempted. A 
physician, who was blinded to the randomization 
assignment, visited each patient at 6 hours, 24 hours 
and 72 hours after leaving the OR. This physician 
evaluated the folowing parameters: severity of 
nausea, pain (at rest and with movement) and 
pruritus; incidence of vomiting; and amount of 
supplementary pentazocine, diclofenac sodium, and 
metoclopramide from 0～6, 6～24 and 24～72 hours 
after leaving the OR.  Other complications from 0～
72 hours after leaving the OR were also evaluated. 
For the evaluation of nausea, pain (at rest and with 
movement) and pruritus, the patients were asked to 
respond with one of the folowing five words: “nai” 
(none), “sukoshi” (little), “tyuugurai” (moderate), 
“tsuyoi” (severe), or “taerarenai” (unbearable). The 
results provided a verbal-rating score (VRS) for the 
severity of each symptom. The evaluation of vomiting, 
amount of supplementary drugs used and other 
complications were based on postoperative records 
and the patient interview. The primary endpoint was 
the incidence of PONV in the first 24 hours after the 
operation. It was defined as the fraction of patients 
that vomited or felt little, moderate, severe or 
unbearable nausea from 0～24 hours after leaving the 
OR. Secondary endpoints were the severity of nausea 
and the incidence of vomiting from 0～6, 6～24 and 24
～72 hours after leaving the OR.
Statistical analysis
　We considered that the incidence of PONV in the 
first 24 hours after the operation would be 40% in the 
CEPI group based on unpublished data and 20% in 
the IV group based on repeated IV infusion in the 
setting of PCA10),11). Therefore, we estimated that a 
sample size >92 was needed to detect a ≥20% 
diference in the incidence of PONV between the two 
groups (assuming a two-sided α error of 0.05 and 
80% power)12).
　Data values are expressed as means±SD, medians 
[minimum-maximum] or numbers and percentages.  
Statistical comparisons between the two groups were 
performed using an unpaired t-test or a chi-square 
test for patient characteristics, vomiting and the 
incidence of PONV.  The severity of nausea, pain, and 
pruritus and the amount of supplementary drugs 
were compared between groups using a Mann-
Whitney U test. Al analyses were performed with 
PASW® statistics 18 (SPSS, Chicago, USA). P values 
< 0.05 were considered significant.
Results
　Among the 293 patients enroled, 71 patients were 
excluded because of the exclusion criteria or because 
they declined to participate in the study. After 
randomization, 17 patients were excluded for the 
folowing reasons: eight patients failed to complete 
the protocol, three patients developed acute ilness 
(one thyroid crisis, one severe bradycardia and one 
dural puncture), and six patients had unscheduled 
bowel resection during the surgery that changed the 
postoperative management.  Therefore, 205 patients 
were included in the final analysis, 103 in the CEPI 
group and 102 in the CIVI group.
　The patient characteristics are shown in Table 1. 
There were no significant diferences between the two 
Okada
－ 54 －
　　　　　Table 1. Patient characteristics
Values are means ± SD or numbers (percentages). There were no significant differences between the groups.
Hy, hysterectomy; Ad, adnexectomy; Om, omentectomy; PL, pelvic lymphadenectomy; PaL, para-aortic 
lymphadenectomy, CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
groups. The numbers of patients with a PONV risk 
factor were not significantly diferent between the 
two groups (Table 1).
　The incidence of PONV in the first 24 hours after 
the operation was 37.9% in the CEPI group and 
32.4% in the CIVI group. There was no significant 
diference between the two groups (p= 0.496).
　The PONV results are shown in Table 2. The 
respective fraction of patients that replied none, little, 
moderate, severe or unbearable for the severity of 
postoperative nausea from 0～6, 6～24 and 24～72 
hours after leaving the OR was not significantly 
diferent between the two groups. Likewise, the 
incidence of postoperative vomiting during each of the 
three time periods was not significantly diferent 
between the two groups. The amount of supplemen-
Table 2. The severity of PONV during the first 72 hours after leaving the operating room. 
CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
Values are numbers (percentages) or medians [minimum-maximum]. There were no significant 
differences between the two groups. 
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tary metoclopramide used in each group from 0～6, 6
～24 and 24～72 hours after leaving the OR ranged 
from 0～30 mg. The median value was 0 for al time 
periods in each group, and there were no significant 
diferences between the two groups.
　For postoperative pain (at rest and with move-
ment), the respective fractions of patients that replied 
none, little, moderate, severe or unbearable from 0～
6, 6～24 and 24～72 hours after leaving the OR were 
not significantly diferent between the two groups 
(Table 3). The amount of supplementary pentazocine 
and diclofenac sodium used from 0～6, 6～24 and 24～
72 hours after leaving the OR in both groups ranged 
from 0～30 mg and 0～75 mg, respectively. The 
median value was 0 for both drugs during al three 
time periods in both groups, and there were no 
significant diferences between the two groups (Table 
3). For pruritus, the respective fraction of patients 
that replied none, little, moderate, severe or 
unbearable was not significantly diferent between 
the two groups (Table 4).
　There were a few other complications that occurred 
from 0～72 hours after leaving the OR. Nine patients 
(8.7%) in the CEPI group and seven patients (6.9%) in 
the  CIVI  group  developed  hypotension  (SBP 
<80mmHg). Al of these patients recovered with only 
fluid therapy. The incidence of hypotension was not 
significantly diferent between the two groups. In 
Table 4. The severity of pruritus during the first 72 hours after leaving the operating room. 
CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
Values are numbers (percentages). There were no significant differences between the two groups.
Table 3. The severity of pain during the first 72 hours after leaving the operating room. 
CEPI: CEPI group (n=103), CIVI: CIVI group (n=102)
Values are numbers (percentages) or medians [minimum-maximum]. There were no significant 
differences between the two groups. 
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addition, one transient ischemic attack, one asthmatic 
attack and two cases of ileus occurred in the CIVI 
group. Those patients recovered without invasive 
treatment. One patient in the CEPI group developed 
restlessness and an extrapyramidal reaction was 
suspected. The patient recovered after the end of the 
droperidol injection. There were no other major 
complications in either group.
Discussion
　This study compared CEPI with CIVI of droperidol 
for the prophylaxis of PONV in patients undergoing 
gynecologic surgery with continuous epidural analge-
sia. The incidence of PONV, postoperative pain (at 
rest and with movement), pruritus, and other 
complications was not significantly diferent between 
the two groups. The eficacy of droperidol was not 
diferent comparing CEPI with CIVI.  There were no 
advantages of CEPI over CIVI.
　In this study, the dosage of droperidol given by CIVI 
for the prophylaxis of PONV was based on the dosage 
recommend for IV PCA (a single bolus of 0.625~1.25 
mg during anesthesia folowed by an infusion of 
0.05~0.1 mg per mg of morphine, as required)5).  
Klahsen, et al. reported that the PCA with a 1 mg IV 
bolus of droperidol folowed by an infusion of 0.04 mg 
per mg of morphine resulted in 3.9±1.12 mg of 
droperidol administrated in the first 24 hours 
postoperatiely13).  On the other hand, the dosage of 
droperidol administered by CEPI for the prophylaxis 
of PONV was reported to be 2.5-5 mg per day6)-9), and 
this was similar to the dosage for CIVI. Therefore, we 
administrated the same total dose to the patients in 
the CEPI and CIVI groups to alow a valid comparison 
between the groups. The dosage of droperidol given to 
both groups was 3.75 mg in the first 24 hours 
postoperatively, and this should have been suficient 
to prevent PONV.
　Recently, the risk factors for PONV in adults were 
reported. Gan et al. reviewed the risk factors for 
PONV in adults14). They indicated that the wel-
established risk factors for PONV include female 
gender, nonsmoking status, history of motion sickness 
or PONV, intraoperative and postoperative opioid 
administration, prolonged duration of surgery and 
the use of volatile anesthetics or neostigmine (>2.5 
mg)14). These risk factors also apply to Japanese 
patients15). The presence of multiple risk factors also 
increases the incidence of PONV16). Because of the 
detailed analysis of risk factors for PONV in our 
study, we believe that our results may be more 
accurate than the results of previous studies.
　Droperidol has antiemetic activity due to the 
antagonism of dopamine (D2) receptors at the 
chemoreceptor trigger zone (CTZ) in the brain stem 
(area postrema)17),18). Droperidol administered by the 
epidural route may be absorbed from the epidural 
space into blood or cerebrospinal fluid (CSF). 
Droperidol absorbed into blood is delivered to the 
CTZ via the systemic circulation, whereas droperidol 
absorbed into CSF is delivered to the CTZ via the CSF 
circulation8), 9).
　However, it is uncertain which route of delivery of 
droperidol to the CTZ is most important. Nakata et 
al.8) reported that delivery via the CSF circulation was 
more important than delivery via the systemic 
circulation, because the blood concentration of 
droperidol after bolus epidural injection was only half 
of that after bolus IV injection19), and the antiemetic 
efect of droperidol was similar comparing bolus IV 
injection with CEPI8). In contrast, Sanansilp et al.9) 
indicated that absorption into blood was more 
important, because droperidol is nonpolar and not 
easily absorbed into CSF.  In our study, the incidence 
of PONV was not diferent comparing CEPI and CIVI 
of droperidol. Since droperidol may enhance the efect 
of analgesics11) and inhibit epidural morphine-induced 
pruritus20), we expected analgesic and antipruritic 
efects in the CEPI group. However, these efects were 
not observed. Therefore, we speculate that the 
antiemetic efect of droperidol administered by CEPI 
was due to absorption into the systemic circulation, 
similar to that obtained by CIVI. Namely, the 
pharmacokinetics of droperidol given by CEPI are 
similar to the pharmacokinetics of droperidol given by 
continuous intramuscular injection.
　In a previous study, Sanansilp et al.9) compared 
epidural injection with IV injection of a single 
droperidol bolus. They found that IV injection was 
superior to epidural injection for the prophylaxis of 
PONV and for antipruritic activity9). To account for 
intravenous versus epidural droperidol
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the diference between their results and our results, 
we speculate that the duration of action of droperidol 
given by bolus epidural injection is shorter than that 
of droperidol given by bolus IV injection, because the 
blood concentration of droperidol after bolus epidural 
injection was only half of that observed after bolus IV 
injection19). However, CEPI should keep the blood 
concentration of droperidol high enough to prevent 
PONV.  A dose-response relationship has never been 
established  for  the  prophylaxis  of  PONV  by 
droperidol in the setting of PCA4).
　This study has several limitations. First, this study 
was performed at a single institution. Second, the 
CIVI of droperidol is not used in routine clinical 
practice for the prophylaxis of PONV. Although the 
same dose of IV droperidol was administered as that 
used in the setting of PCA, droperidol in PCA is not 
constant IV injection. Third, we did not measure any 
blood concentrations of droperidol in this study.
conclusion
　The eficacy of droperidol was not diferent 
comparing CEPI with CIVI. The CEPI of droperidol 
was a useful prophylaxis of PONV for the patients 
undergoing continuous epidural analgesia.
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Introduction
　Intraductal papilary-mucinous neoplasms (lPMNs) 
are tumors that are classified as true neoplastic cysts 
of the pancreas. IPMNs are characterized by large 
quantities of mucous production, opening of Vater’s 
papila, pancreatic duct dilation, papilomatous 
proliferation of the pancreatic duct, and poor 
infiltration. Although prognosis is excelent in 
noninvasive cases, the postoperative 5-year survival 
rate of invasive cases is 40%–50%. The male to female 
ratio is 2:1. IPMNs are common among elderly 
individuals (mean age for both genders, approxi-
mately 65 years). The preferred site of IPMNs is the 
pancreatic head, which accounts for up to 70% of 
cases1).
　The concept of an IPMN was first reported by 
Ohhashi et al2), who described it as a ‘mucin-
producing pancreatic tumor.’ Since 1990, this 
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disease concept has been confirmed worldwide by the 
Japanese Classification of Pancreatic Carcinoma3), the 
Armed Forces Institute of Pathology4), the Interna-
tional Histological Typing of Tumors of the Exocrine 
Pancreas by the World Health Organization5), and by 
Kimura et al6)-8). Moreover the International Consen-
sus Guidelines for Management of IPMNs were 
published in 20069). In recent years, the concept of a 
new classification of IPMNs, based on immunohisto-
logical subtypes, which was revised according to the 
WHO classification in 2010, has been adopted11), and 
the international consensus guidelines of 2012 for the 
management of IPMN and MCN of the pancreas have 
been published10).
　Our group, Takasu et al12) previously reported a 
retrospective comparative study of the clinicopa-
thological features, degree of malignancy, morphologi-
cal and immunohistological findings and prognosis of 
IPMNs. That study divided IPMNs into the folowing 
four subtypes: gastric, intestinal, pancreatobiliary, 
and oncocytic. Furthermore, IPMNs were histopathol-
ogicaly classified as adenoma/borderline (IPMN with 
low- or intermediate-grade dysplasia), carcinoma in 
situ (IPMN with high-grade dysplasia), or invasive 
carcinoma derived from IPMN (IPMN with an 
associated invasive carcinoma), in which cancer 
development was described according to staging. 
Moreover, Takeshita et al13) from our group reported 
that an MIB-1 labeling index (Ki67) could be used as 
an indicator of the degree of malignancy. However, 
there has not yet been any study in which the 
association between the MIB-1 labeling index (Ki67) 
and the four morphological and immunohistological 
subtypes was investigated. The present study 
therefore aimed to examine the relationship between 
the MIB-1 labeling index (Ki67) and the four 




　Between 2000 and 2007, we retrospectively 
evaluated 46 patients who had undergone surgery at 
the Department of Gastroenterological and General 
Surgery, Yamagata University, Faculty of Medicine, 
Japan, were histopathologicaly diagnosed as IPMN, 
and in whom immunohistochemical staining was 
possible. Clinical and folow-up information was 
obtained from patient charts.
Subclassification of IPMNs
　The 46 IPMN patients were graded as adenoma/ 
borderline (adenoma, in this paper), carcinoma in 
situ, or invasive carcinoma derived from IPMN 
according to their histological grade. This grading 
corresponded to the WHO IPMN subtype classifica-
tion11) of IPMN with low-/intermediate-grade dyspla-
sia, IPMN with high-grade dysplasia, and IPMN with 
an associated invasive carcinoma, respectively. 
Adenoma (IPMN with low- or intermediate-grade 
dysplasia) showed papilary growth, consisted of a 
higher proportion of columnar cels than the other 
subtypes, and maintained a proper nuclear arrange-
ment as assessed by hematoxylin and eosin (H-E) 
staining. Carcinoma in situ (IPMN with high-grade 
dysplasia) showed a lack of proper nuclear arrange-
ment, enlargement of the nucleus, a definite nuclear 
pole, and a high level of mitosis. We defined invasive 
carcinoma derived from IPMN (IPMN with an 
associated invasive carcinoma) as cancer cels that 
infiltrated  the  basal  membrane  and  invaded 
interstitial connective tissue.
　The 46 cases of IPMN were subclassified into 4 
types (Gastric, Intestinal, Pancreatobiliary, and 
Oncocytic) as described by Furukawa et al14) on the 
basis of their morphological features and their 
immunohistochemical reactivity (MUC1, MUC2, and 
MUC5AC staining). The samples were first classified 
on the basis of their H-E stained findings, after which 
immunohistochemical analysis was performed to 
confirm the results. When the assessment made on 
the basis of H-E staining was inconsistent with the 
immunohistochemicaldata, the H-E stained slides 
were rechecked. If the H-E data remained inconsis-
tent with the immunohistochemical analysis, the H-E 
based  assessment  was  used  rather  than  the 
immunohistochemical based assessment12).
Immunohistochemical staining
　Immunohistological staining was performed using 
the streptavidin-biotin method. Resected specimens 
MIB-1 for Gastric Type IPMN
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were fixed with formalin and embedded in parafin. 
Thin serial sections were made with a microtome. 
After deparafinization, sliced specimens were washed 
with phosphate-bufered saline. The specimens were 
then heated three times in a microwave at 900 W for a 
total of 30 minutes at 100°C. Endogenous peroxidase 
was blocked with 0.3% H2O2. Non-specific staining 
was blocked by incubating the sections in a solution 
containing  3%  skim  milk.  The  sections  were 
subsequently  incubated  with  primary  antibody 
overnight at 4°C. Next, the sections were incubated 
with  a  second  biotinylated  mouse  monoclonal 
antibody  and  peroxidase-labeled  streptavidin 
(LSAB kit; Dako, Glostrup, Denmark) for 1 hour. 
Peroxidase  activity was  then  detected  using 
3,3’-diaminobenzidine. Finaly, counterstaining was 
performed with hematoxylin. The primary antibodies 
used were specific for MUC1 (clone Ma695; dilution 
1:100) (NovoCastra Laboratories, Newcastle upon 
Tyne, UK), MUC2 (clone Cep58; dilution 1:200) 
(NovoCastra Laboratories), MUC5AC (clone CLH2; 
dilution 1:100) (NovoCastra Laboratories), or the 
Ki67 antigen (clone MIB-1; dilution 1:120) (Dako, 
Glostrup, Denmark).
Evaluation of MUC1, MUC2, and MUC5AC staining
　Two to four slides were immunohistochemicaly 
stained per case. The entire neoplasm on each slide 
was microscopicaly examined under low power (×10) 
and the approximate percentage of positively stained 
neoplastic cels was calculated. The neoplasms were 
graded as folows: (-) less than 5% of neoplastic cels 
positive, (+) 5% to 50% of neoplastic cels positive, 
and (++) more than 50% of neoplastic cels positive. 
For invasive carcinoma derived from IPMN, only the 
noninvasive sites were evaluated: sites of apparent 
invasion were not assessed.
Evaluation of MIB-1 staining
　Two to three slides were immunohistochemicaly 
stained per case. More than 5 fields were selected at 
random  and  microscopicaly  analyzed.  In  one 
particular case, five areas were chosen and analyzed 
at a higher magnification (×200). More than 2000 
tumor cels were countedper case. The MIB-1 labeling 
index was calculated as the percentage (%) of the total 
tumor cels that stained positive. In invasive 
carcinoma derived from IPMN, only the noninvasive 
sites were evaluated: sites of apparent invasion were 
not assessed.
　Al of the pathological and immunohistochemical 
investigations of IPMNs were performed, and the 
results were confirmed, by two physicians.
Statistical analysis
　Results are expressed as means ± SD (range). 
Continuous variables were analyzed using Student’s 
t-test. Survival was calculated from the date of 
resection to the date of disease-specific fatality or to 
the date of censoring at the last folow-up. 
Cumulative overal survival rates were calculated 
using the Kaplan-Meier method. Statistical signifi-
cance was defined as P < 0.05. Al analyses were 
carried out using the StatView version 5.0 Software of 
the SAS Institute, Inc.
Results
　Patient clinicopathological characteristics (n = 46) 
are shown in Table 1. The mean age of the patients 
(32 males and 14 females) was 67 ± 10 years (range, 
47–87). Pancreaticoduodenectomy15) was performed 
in 26 patients, distal pancreatectomy with splenec-
tomy in 9, spleen-preserving distal pancreatectomy16) 
in 10, and total pancreatectomy in one patient. 
Histological grade was: adenoma (n = 27), carcinoma 
in situ (n = 9), and invasive carcinoma derived from 
IPMN (n = 10). Subtypes, based on morphological 
features and immunohistochemical reactivity, were as 
folows: gastric (n = 20), intestinal (n =15), panacrea-
tobiliary (n = 9), and oncocytic (n = 2). The overal 
MIB-1 labeling index for al patients was 8.6% ± 9.2% 
(range, 0.34%–29%). The MIB-1 labeling index (Ki67) 
of patients with the gastric type was 4.0% ± 6.8%, 
which was significantly less than that for patients 
with intestinal or pancreatobiliary types (Figure 1). In 
patients with the gastric type there were significantly 
more adenomas observed (n = 17, 86%) than 
carcinomas in situ (n = 3) or invasive carcinomas 
derived from IPMN (n = 0) (Table 2). Similar 
numbers of each histological gradeof tumor were 
found in the intestinal type. Adenomas and invasive 
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　　　　　　　　　　　Table 1. Clinicopathological characteristics of 46 IPMN patients
PD, pancreaticoduodenectomy; DPS, distal pancreatectomy with splenectomy, SPDP, spleen-preserving distal 
pancreatectomy; TP, total pancreatectomy; Adenoma, IPMN with low- or intermediate-grade dysplasia, adenoma, 
or borderline; Carcinoma in situ, IPMN with high-grade dysplasia or non-invasive carcinoma; Invasive carcinoma 
derived from IPMN, IPMN with an associated invasive carcinoma. 
carcinomas derived from IPMN were the most 
common histological grades found in the pancreatobil-
iary type (both, n = 4). The MIB-1 labeling index 
(Ki67) of patients with adenoma and the gastric type 
of IPMN was less than that for patients with 
adenoma and the intestinal type of IPMN (p = 0.04). 
There was no significant diference between the MIB-
1 labeling index of patients with carcinoma in situ 
and the gastric type of IPMN and that for patients 
with carcinoma in situ and the intestinal type of 
IPMN. The survival curve for al 46 patients with 
IPMN is shown in Figure 2. The mean observation 
period was 68.6 ± 36.9 months (range, 6–153 
months). There were seven disease-specific fatalities, 
al of which were invasive carcinomas derived from 
IPMN, including 1, 4, and 2 patients with intestinal, 
pancreatobiliary, and oncocytic subtypes, respectively. 
The 5-year overal survival rate was 84.3%.
　The relationship between survival and MIB-1 
labeling indices of <10% and ≥10% is shown in 
Figure 3. There were no disease-specific fatalities in 
patients with an MIB-1 labeling index of <10%, 
whereas in those with an index of ≥10%, the 5-year 
survival rate was 61.1% and the prognosis was 
apparently poor.
Figure 1. MIB-1 labeling indices of each immunohisto-
logical subtype of IPMN
　Data are shown as means (thick bars) + standard 
deviations (thin bars).
　The MIB-1 labeling index (Ki67) of patients with the 
gastric type was significantly less than that for patients 
with intestinal or pancreatobiliary types.
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Table 2. Histological grading and MIB-1 labeling index (Ki67) of IPMNs according to immunohistological subtypes
Adenoma, IPMN with low- or intermediate-grade dysplasia, adenoma, or borderline; Carcinoma in situ, IPMN with 
high-grade dysplasia or non-invasive carcinoma; Invasive carcinoma derived from IPMN, IPMN with an associated 
invasive carcinoma; NS, no significant. MIB-1 labeling indexes are expressed as mean ± standard deviation.
* showing actual values. 
Discussion
　Various gastrointestinal cancers are classified 
according to cel and tissue morphology and a 
correlation with clinicopathological characteristics 
and prognosis is acknowledged. Lauren17) classified 
gastric carcinoma into difuse and intestinal types 
and demonstrated that these types correlated with 
clinical characteristics. Kimura et al18) were the first 
to use the terms intestinal type and pancreatobiliary 
type in carcinoma of the papila of Vater, and they 
reported that cases of the pancreatobiliary type had a 
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Figure 3. Correlation of survival curves with MIB-1 
labeling indices of < 10% and ≥10%
　There were no disease-specific fatalities in patients 
with an MIB-1 labeling index of <10%, whereas in those 
with an index of ≥10%, the 5-year survival rate was 
61.1% and the prognosis was poor.
Figure 2. Survival curves of al 46 patients with IPMN
　The mean observation period was 68.6 ± 36.9 months, 
and the 5-year survival rate was 84.3%.
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　The folowing two classification systems were 
created for IPMNs: Adsay et al19) divided the condition 
into intestinal, pancreatobiliary, and nul types, 
whereas Yonezawa et al20) created two categories: 
vilous dark cel and papilary clear cel types. In a 
further report by Adsay et al21), these authors 
described the concept of intraductal oncocytic 
papilary neoplasms, in which the papila, comprising 
eosinophilic cels, exhibits a complex branching form. 
In 2005, Furukawa et al14) reported a consensus study 
regarding a new IPMN classification that integrated 
these two schools of thought, in which IPMN was 
classified into the folowing four subtypes: gastric, 
intestinal,  pancreatobiliary,  and  oncocytic.  This 
concept was adopted by WHO as their new 
classification system in 201011). We classified the 46 
patients in our study into four subtypes according to 
the classification system of Furukawa et al14). 
According to this system, the histopathological 
subtype  of  IPMN  should  first  be  based  on 
morphological characteristics and then confirmed by 
immunohistological staining. Our study was based on 
this concept. When findings from H–E staining 
difered from those of immunohistological staining, 
we based the classification on both H–E staining and 
the pathological findings colected from at least two 
physicians. However, only a few such cases were 
found in this study. In our group, the prognosis of 
patients with the gastric or intestinal types was more 
favorable than that for patients with the pancreatobil-
iary type12). Moreover, the prognosis of patients with 
invasive carcinomas derived from IPMN tended to 
be better for the intestinal type than for the 
pancreatobiliary type, which may suggest that the 
former is a slow-growing neoplasm.
　IPMN grading for atypia was histopathologicaly 
classified  into  adenoma  (IPMN  with  low- or 
intermediate-grade dysplasia), carcinoma in situ 
(IPMN with high-grade dysplasia), or invasive 
carcinoma derived from IPMN (IPMN with an 
associated invasive carcinoma), in which cancer 
development is described according to staging. 
Takeshita et al13) demonstrated that the MIB-1 
labeling index, Ki67, was higher for patients with 
carcinoma in situ than for patients with adenoma; 
thus, the MIB-1 labeling index was considered as an 
appropriate indicator of the degree of malignancy. 
These authors also suggested that when IPMN is 
diagnosed as carcinoma in situ, it should be surgicaly 
removed.
　On the basis of these two reports, we examined the 
relationship between the MIB-1 labeling index, Ki67, 
which is an indicator of malignancy, and the four 
diferent  morphological  and  immunohistological 
subtypes of IPMN. We found that the MIB-1 labeling 
index  of  patients  with  the  gastric  type  was 
significantly lower than that of patients with the 
other subtypes (Figure 1). Moreover, of the 46 
patients, those with an MIB-1 labeling index of less 
than 10% showed no decrease in survival time after 
surgery  (Figure 3).  In  summary,  our  findings 
regarding the MIB-1 labeling index demonstrate that 
patients with the gastric type, who have a low MIB-1 
index, exhibited a lower degree of malignancy than 
those with other subtypes, who have a higher MIB-1 
index, and that their prognosis was good.
　Similarly, Furukawa et al22) also demonstrated that 
overal prognosis was better for patients with the 
gastric type of IPMN than for patients with other 
IPMN subtypes. It has been postulated that gastric 
type IPMN often displays low- or intermediate-grade 
dysplasia and that malignant transition occurs less-
frequently in patients with gastric type IPMN10), 11). In 
the present study, although adenoma was frequently 
found in patients with gastric type IPMN, invasive 
carcinoma derived from IPMN was not found in these 
patients. On the other hand, some previous studies 
have shown that patients with invasive carcinoma 
derived from gastric type IPMN, which often takes 
the histological finding of tubular adenocarcinoma, 
have a worse prognosis than patients with invasive 
carcinoma derived from intestinal type IPMN22), 23). In 
2002, Adsay et al26) suggested that MUC2-positive 
IPMN, i.e. the intestinal type, whose carcinogenesis 
folows a pathway similar to the adenoma-carcinoma 
sequence in colorectal cancer, is "indolent" disease, 
whereas MUC1 positive IPMN, i.e. the pancreatobili-
ary type, is "aggressive" disease similar to pancreatic 
adenocarcinoma. In addition, there is increasing 
evidence that gastric type IPMN shows a significantly 
higher incidence of KRAS mutations24), and no 
incidence of GNAS mutation compared with the 
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intestinal type25). It has been suggested that the 
carcinogenesis of not only the pancreatobiliary type 
but also the gastric type of IPMN may be the same as 
that of pancreatic adenocarcinoma24), 25). In the light of 
these studies, it is interesting to note that the MIB-1 
labeling index of patients with the gastric type 
difered from that of the intestinal type in this study.
　In the present study, no invasive carcinoma derived 
from IPMN was detected in patients with the gastric 
type, and the MIB-1 labeling index of this type was 
significantly less than that of the other subtypes. 
These results may be due to a diference in 
histological grade of the neoplasm. However, the 
MIB-1 labeling index of patients with the gastric type 
was only less than that of patients with the intestinal 
type for neoplasms that were graded as adenomas. We 
concluded that malignancy of the gastric type of 
IPMN not higher and may be lower than that of other 
subtypes. Although patients with the gastric type of 
invasive carcinomas derived from IPMN may have 
poor prognoses22), 23), such cases were not found in this 
study of 46 cases. We therefore suggest that such 
cases may be rare and, consequently, more of such 
cases should be accumulated for further study.
　In conclusion, gastric type intraductal papilary 
mucinous neoplasms have a low MIB-1 labeling index, 
which demonstrates that malignancy of this subtype 
is lower than that of other subtypes.
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　The mortality rate due to Acute Respiratory 
Distress Syndrome (ARDS) is currently 40%.1) 
Although progress has been made in treatments for 
ARDS, the survival rate after one year has not 
improved2).  Ashbaugh3)　 First  described  serious 
hypoxia-related respiratory failure ARDS in 1967, and 
Bernard et al.4) proposed a definition for ARDS in 
1994. At the time ARDS was defined as acute onset 
hypoxemia, with bilateral difuse shadows on chest X-
ray, and not dependent on heart failure. It can be 
classified into Acute Lung Injury (ALI) and ARDS 
based on the PaO2/FIO2 (P/F) ratio. However, in 
several clinical studies based on this definition, most 
treatment strategies, such as artificial ventilation, 
drug therapy, anti-cytokine therapy, and others, were 
found to be without a lung protective strategy5).
　In addition, the mortality rate due to ALI and 
ARDS remained nearly unchanged6), which indicated 
that this definition was problematic. ARDS is now 
referred to as a syndrome, and survival rates are 
dependent on the primary disease and severity. This 
includes whether the origin is pulmonary (primary) 
or extra-pulmonary (secondary). Thus, it was unclear 
regarding what type of treatment was appropriate.
　A new definition for Acute Respiratory Distress 
Syndrome (ARDS) was proposed in 2011 by the 
European Society of Intensive Care Medicine7), 8). This 
classified ARDS into three grades based on the P/F 
ratio: Mild ARDS (P/F = 300-200), Moderate ARDS 
(P/F = 200-100), and Severe ARDS (P/F/< 100), while 
on respiratory care with PEEP of > 5 cmH2O (Table 
1). 
　Thus, the indications for treatment could be 
demonstrated using many types of respiratory care 
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　Acute Respiratory Distress Syndrome stil high has a mortality rate. There are many causes for 
respiratory failure including sepsis, aspiration, pneumonia, pancreatitis, chest trauma, transfusion, and 
so on. However, not only respiratory failure, but the mechanical ventilation itself could induce lung 
injury additionaly. 
　Recently there has been a new definition of ARDS that is based on the clinical findings, time course of 
onset, and PaO2/FIO2 with more than 5 cmH2O of PEEP. It does not include heart failure and over 
infusion. Respiratory care for ARDS is going to change, as a result of recent research into respiratory 
management. In this review we describe respiratory care evidence for ARDS in terms of the Berlin 
definition, the history of naming ARDS, pathophysiology, etiology, ventilator management that are tidal 
volume, PEEP, High frequency ventilation (HFO), non-invasive positive pressure ventilation (NPPV), 
and airway pressure release ventilation (APRV). The physiotherapy of the prone positioning and 
recruitment maneuver (RM), Extra Corporeal Membrane Oxygenation (ECMO), nitroxide (NO), 
intravenous muscle relaxants, and so on wil be discussed.
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Figure 1. Severity of ARDS by P/F and Intervention.
　The respiratory treatment that are based on the 
evidence is indicated depending on the severity of ARDS. 
Low tidal volume ventilation is  recommended for al 
grades of ARDS.  Low PEEP for Mild to Moderate 
ARDS and Higher PEEP for Severe ARDS were 
recommended.  NPPV  is  for  Mild  ARDS,  Prone 
positioning is for Severe ARDS with high level of 
recommendation. The others are shown as wel with low 
grade of it.
Table 1. The Berlin definition7), 8)
　Onset of timing was stated within one week. Chest 
imaging and origin of edema were not changed compare 
with previous definition. However, as the most 
important points ARDS was classified to three grades by 
PaO2/FIO2 with more than 5 cmH2O of PEEP. These are 
Mild, Moderate, and Severe ARDS.
according to this grade classification. Here, we 
describe the pathophysiology of ARDS and provide 
explanations for the indicated respiratory care based 
on the new advocated definition.
(A) Etiology and pathology of ARDS
　Although the cause of ARDS comes from many 
factors, it is always initiated when an external 
stimulus, such as endotoxin, activates alveolar 
macrophages via Tol-like receptors (TLRs). These 
activated macrophages produce and release cytokines, 
such as Il-8, which activate neutrophils. These 
neutrophils attach to a pulmonary blood vessel wal, 
rol along on a capilary, and then invade through 
intercelular gaps into interstitial tissue. Leukotrie-
nes, oxidants, PAF, proteases and other mediators are 
also released from these cels. These mediators 
decrease surfactant activity, induce alveolar colapse, 
and increase the permeability of blood vessels and 
edema in the lungs. They also promote the formation 
of hyaline films, necrosis of type I cels, celular 
apoptosis, colagen production, and clot formation, 
which results in an inflammatory reaction9). Pulmo-
nary mechanics also worsen and require respiratory 
management.
(B) Berlin Definition7), 8)
　The currently used definition of ARDS was first 
advocated in Berlin, Germany. Respiratory failure 
with excessive infusion and/or heart failure are 
excluded for this definition of ARDS. As noted above, 
ARDS is classified into three categories based on the 
P/F ratio while performing respiratory management 
with PEEP of > 5 cmH2O for respiratory failure 
within one week after onset (Table 1).
　In addition to the abnormal findings on chest X-ray 
that showed difuse shadows on both sides, there were 
increased pathophysiological abnormalities, such as 
the volume of one minute ventilation, dynamic and 
static compliance, and the amount of extravascular 
lung water.
　It is particularly noteworthy that they demon-
strated an efective respiratory management strategy 
according to severity based on empirical evidence 
(Figure 1).  By investigating pathological views of the 
lungs in terms of the classifications in this definition, 
there is a good relationship between clinical severity 
and pathological findings10). Some reports11) supported 
that extra-vascular lung water volume and pulmo-
nary blood vessel permeability are good indicators for 
classifying ARDS.
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(C) Respiratory management for ARDS
(1) Smal Tidal Volume
　Conclusion was reached that restrictive ventilation 
was efective for treating ARDS regardless of severity, 
as the smal tidal volume used for ARDS was 
demonstrated to improve mortality by the ARDS net 
in 20005). They discovered that the survival rate 
increases after the reduction of ventilator-induced 
lung injury by non-physiological artificial ventilation. 
In addition they observed that the smal tidal volume 
reduces the over-stretching of alveoli and smal 
airways, which is caled volume trauma or barotrau-
ma12). This is also caled bio-trauma because hyper-
extension of the lung induces the release of chemical 
mediators, such as cytokines, to promote an 
inflammatory reaction13). Furthermore in a separate 
clinical study, they found that if the peak inspiratory 
pressure was < 31cmH2O, the convalescence was not 
afected regardless of the amount of tidal volume in 
ARDS patients14).
(2) PEEP
　Even though if low tidal volume is used, if an 
inappropriate PEEP level is added, lung injury wil 
increase. A representative pressure-volume curve 
measured during artificial respiration of an ARDS 
patient is shown in Figure 2. There are two points on 
the steep curve, which are caled the lower inflection 
point (LIP) and the upper inflection point (UIP)10).  
Lung injury is relieved in terms of a restricted peak 
inspiratory pressure of < UIP and also using PEEP 
higher than the LIP. PEEP less than LIP produces 
shear stress by repeated alveolar colapse and re-
opening, and is known to bring about an inflamma-
tory reaction. Although there have been numerous 
studies since the 1960s regarding the best PEEP 
level, there is stil no consensus regarding the method 
that provides the most suitable PEEP level in order to 
improve the survival rate, which was pointed out by 
Slutsky  et  al.15)  Maeda  et  al.16)  performed  a 
randomized controled trial (RCT) for 987 ARDS/ALI 
patients with P/F ratios of < 250 and compared a high 
PEEP group with a low PEEP group. They compared 
survival rates and other outcomes after randomiza-
tion for 75 days, but could not find significant 
diferences (P < 0.18). Gattinoni et al.17) described 
that even if a high PEEP level was applied randomly 
to indefinite ALI/ARDS patients, the prognosis did 
not improve. Briel at al.18) investigated the survival 
rates of 2,299 ALI/ARDS patients by comparing a 
High PEEP (HP) group with a Low PEEP (LP) group 
based on three RCTs. For al of these patients, there 
was no diference in the survival rate as reflected by 
32.9% of the HP group vs. 35.2% of the LP group (CI: 
0.86-1.04; p = 0.25). However, for 1,892 of these 
ARDS patients with P/F ratios of < 200, the mortality 
rate of the HP group (34.1%) was lower than that of 
the LP group (39.1%). In addition, among 404 ALI 
patients the mortality rate in the HP group (27.2%) 
was higher than that in the LP group (19.4%) (CI: 
0.98-1.92; p = 0.07). These results provided some of 
the best evidence that PEEP level should be low for 
mild to moderate ARDS and should be high for 
moderate to severe ARDS.
(3) Recruitment and Prone Position Management
　The principle of recruitment can be explained based 
on a pressure volume curve (Figure 2). At the 
beginning, ARDS lungs have low compliance. If the 
airway pressure increases, then the compliance (⊿V/⊿
Figure 2. Pressure-Volume curve of the injured lung10)
　The ventilator induced lung injury (VILI) was 
considered to occur by shear stress with alveolar colapse 
and opening, or alveolar over distention which induce 
baro-trauma, volu-trauma and bio-trauma. Protectve 
ventilation is theoreticaly that peak inspiratory 
pressure had better keep less than Upper inflection 
point and PEEP also should set up at more than 
Inflection point.
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P) improve beyond the LIP point. As this pressure 
increases so does the pulmonary capacity, however, 
the compliance wil remain constant between the LIP 
and the UIP. However, compliance decreases again 
after the UIP point. The lung volume at the 
decreasing part of the curve is greater than that at 
the increasing part of the curve with the same airway 
pressure. In other words, the end-expiratory lung 
volume can be kept greater at a lower PEEP level 
than that before recruitment. Recruitment seems to 
prevent lung injury due to keeping alveoli and smal 
airways open. However, this technique does not 
provide evidence of mortality improvements19).
　It is wel known that SaO2 is improved when a 
patient moves from a supine to a prone position while 
undergoing mechanical ventilation. Prone position 
management for ARDS patients came to be positively 
adopted in intensive care units. However, Gattinoni et 
al.20) tried this prone position strategy for ARDS 
patients in a prospective study in 2001 and reported 
that it did not afect the prognosis as compared with 
the supine position. Several reports were subse-
quently published, but did not arrive at a consensus. 
Furthermore, Abrog et al.21) performed a meta-
analysis of five papers regarding prone position 
therapy for ARDS/ALI patients. These included 713 
cases in the prone position and 659 in the supine 
position. Oxygenation was improved with the prone 
position, but did not improve mortality.
　However, Abrog et al.22) subsequently added four 
more papers that included only ARDS patients. This 
included 862 patients for which prone position 
ventilation was performed within total 1675 patients. 
They found no significant diferences among seven 
papers with both ALI and ARDS patients combined.  
However, prone position management over a long 
time reduced the mortality in the ICU in only the four 
latest articles, which were limited to ARDS patients. 
There were no significant diferences in terms of 
complications  between  them,  including  airway 
occlusion, puling out catheters, and circulatory 
complications. According to this report22), the prone 
position strategy was certified to be efective for 
severe ARDS patients. An improved survival rate was 
demonstrated for 10% to more than 15% of severe 
ARDS cases who had P/F/ ratios of < 100 when using 
prone position management23), 24).
(4) Muscle relaxants
　Papazian at al.25) investigated the efectiveness of 
muscle relaxants for 1326 ARDS patients in France.  
These patients were registered after severe ARDS 
was diagnosed with P/F ratios of < 150 and with 
PEEP of > 5 cmH2O. This was a prospective study 
that compared 177 patients in a muscle relaxant 
group and 162 patients in a control group. The muscle 
relaxant of Cisatracrium was administrated at the 
beginning of artificial ventilation up to an upper limit 
of use for 48 hours. The mortality rate was 
significantly lower in the muscle relaxant group than 
in the control group, with 23.7% vs. 33.3% at 28 days 
and 31.6% vs. 40.7% at 90 days, respectively. In the 
muscle relaxant group, there were shorter periods of 
ventilator-free days and fewer complications involv-
ing organ disorders, such as heart failure, liver 
dysfunction, and renal insuficiency, and fewer blood 
coagulation disorders. The muscle relaxant group also 
had fewer instances of barotrauma and pneumotho-
rax, such as ventilator-induced lung injury. However, 
the severity and frequency of complications involving 
muscle atrophy and paralysis were the same in both 
groups. Neto et al.26) also did a meta-analysis to 
investigate three RCTs in which muscle relaxants 
were used for ARDS. This included 431 ARDS 
patients. They found that the mortality rate was 
lower in the muscle relaxant group. In addition, the 
artificial respiration period was shorter, the number 
of other treatments used was fewer, P/F ratios were 
higher, and there were fewer instances of barotrauma, 
such as pneumothorax, as compared with the control 
group. The complication rates of neuromuscular 
disease were the same. They emphasized that early 
administration of a muscle relaxant within 48 hours 
for severe ARDS patients improved mortality with 
the same level of complications26).
　Unsynchronized ventilation seems to induce the 
colapse and hyperextension of the lungs between 
spontaneous breathing and mechanical ventilation. 
This is because the trans-pulmonary pressure 
produced by spontaneous breathing is greater than 
that produced by forced ventilation in the severe 
injury lung model. Additionaly, it has been shown 
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that paradoxical breathing (i.e., Pendluft) occurs in 
the lungs in the case of spontaneous breathing in 
severe lung injury27). For severe ARDS patients, forced 
ventilation with muscle relaxants was supported from 
the beginning of respiratory failure for up to two 
days. However, respiratory care along with observing 
the trans-pulmonary pressure has not yet become a 
standard strategy28), and requires further study.
　As evidence, a limited tidal volume strategy has 
been shown to have a good efect for ARDS. In 
addition, it has been emphasized that non-spontane-
ous ventilation with muscle relaxants is useful for 
those patients with limited ventilation29). This was 
because the relaxant dose administrated was larger in 
the smal tidal group than that used in the control 
group. In the Surviving Sepsis Campaign 201230) it 
was described that muscle relaxants should be 
avoided for non-ARDS patients (evidence level 1C). 
However, muscle relaxants should be administered for 
severe ARDS patients with P/F ratios of < 150 in the 
short term of less than 48 hours during the early 
stage (evidence level 2C).
(5) High Frequency Oscilation (HFO) and
　Airway Pressure Release Ventilation (APRV)
　Again considering a pressure-volume curve, the 
best means to induce the least amount of stress to the 
injured lung is ventilation between the LIP and the 
UIP (Figure 2). The lung compliance in severe ARDS 
decreases and the slope of the PV curve declines 
toward the right. Consequently, the distance between 
the LIP and UIP could possibly shorten. In such a 
case, High Frequency Oscilation (HFO) becomes the 
ideal ventilation method, at least theoreticaly. A few 
decades ago, many clinical studies of HFO for IRDS 
were conducted and succeeded in providing evidence 
for this. HFO is now also used for IRDS of neonates. 
HFO is set at a frequency (number of vibrations) of 10 
HZ from 3 HZ, and with the tidal volume less than 
the dead space. However, HFO airway pressure is 
often at 10 cmH2O higher than the mean airway 
pressure of conventional ventilation.
　Therefore, it is thought that HFO frequently 
induces hypotension or barotrauma. Sud et al.31) 
compared the prognosis of a HFO group and a 
Conventional group by a meta-analysis that included 
about 180 ARDS patients in each group. There were 
no significant diferences in the frequencies of 
complications, such as pneumothorax, hypotension, 
or obstruction of a tracheal tube. From the first day to 
the third day, oxygenation was significantly higher in 
the HFO group than in the control group. In addition, 
the mortality rate at 30 days was lower in the HFO 
than in the control group; 73/189. vs. 87/176 (P < 
0.03). However, the results of the OSCILLATE Trial32) 
conducted by a Canadian group and the OSCAR 
Study33) conducted in the U.K. were recently reported.
　In the OSCILLATE Trial32), HFOV during the early 
stage compared with a lung protective strategy with a 
high PEEP level for moderate-severe ARDS adult 
patients showed that HFOV increased the mortality 
rate and did not improve the prognosis. The actual in-
hospital mortality rate was 47% in the HFOV group 
vs. 35% in the CV group, which showed that HFOV 
deteriorated patients’ conditions. Therefore, the plan 
for 1,200 target patients was canceled for 548 cases. 
The HFOV group received more doses of a muscle 
relaxant and the sedative midazolam. Although the 
mortality was higher with HFOV for ARDS patients 
with P/F ratios of > 86, it was almost the same at 
42%-43% for those with P/F ratios below this value.
　In the OSCAR Study33), HFOV or CV was used for 
795 ARDS adult patients with P/F ratios of < 200 for 
more than two days. There was no significant 
diference between both groups in their mortality 
rates by 30 days, which were 41.7% of 166/398 (HFOV 
group) and 41.1% of 163/397 (CV group). These 
results are seemed to require further discussion.
　Airway pressure release ventilation (APRV) is 
CPAP at high pressure under spontaneous breathing 
while maintaining the lung status at recruitment and 
is also a ventilation mode for promoting carbon 
dioxide removal in terms of moving to a low-pressure 
CPAP for a short time. APRV has been investigated 
for comparing numerous types of ventilation modes, 
including PSV, VC-IRV, PCV, s-IMV, and PC-IMV. 
Those papers emphasized superior points, such as 
improvements of atelectasis, oxygenation, circulatory 
distress, airway pressure, and reduced sedative use.
　However, Gonzalez34) compared prognosis between 
two groups in terms of matching by propensity scores, 
which involved respiratory failure patients including 
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234 cases with APRV and 1,228 cases with assist-
control ventilation (A/C). APRV was not superior to 
A/C in terms of factors such as ventilator free days, re-
intubation, number of days in the ICU, and in-
hospital mortality rates.
(6) NO
　Afshri35) assessed the efectiveness of NO inhalation 
for ARDS/ALI based on 14 RCTs involving 1,303 
patients. They concluded that NO inhalation could 
not be recommended for hypoxemic respiratory 
failure patients. Although NO transiently improved 
oxygenation, it did not result in an increased survival 
rate. There were no problems with regard to bleeding 
or met-hemoglobinemia, but its use did result in the 
development of renal injury that was possibly 
harmful. Although this was a negative result, if cases 
could be limited based on strict evaluations of 
adaptation, it may become a new development in the 
future.
(7) ECMO
　Takeda et al.36) pointed out the problem that 
intensivists and staf members in the ICU were not 
accustomed to using ECMO for ARDS patient during 
the influenza pandemic outbreak in Japan. Other 
issues were the materials and the ECMO system used 
in Japan. In clinical studies, ECMO has been applied 
not only for H1N1 influenza pneumonia, but also for 
various types of respiratory failure in foreign 
countries. It is thought that development of an ECMO 
system wil progress in Japan in the near future37). In 
addition, the Japanese Society of Respiratory Care 
and the Japan Society of Intensive Care Medicine 
have begun to register ARDS patient for ECMO 
therapy. This should contribute to improving the 
mortality of patients with influenza pneumonia 
and/or ARDS in Japan.
(8) NPPV
　In the Berlin Definition, NPPV was adapted only 
for Mild ARDS. However, the level of evidence for 
NPPV use for ARDS patients is not high38), 39). NPPV is 
thought to prevent Mild ARDS from becoming severe 
ARDS by starting NPPV during an early stage before 
any changes are noted on chest X-rays.
　Evidence for using NPPV has been accumulating.  
A high grade of evidence has been provided for acute 
heart failure (1A)40), 41), acute exacerbations of chronic 
obstructive pulmonary disease (1A)42), and respiratory 
failure due to immunodeficiency (2A)43). Now NPPV is 
extensively used for postoperative respiratory failure 
as a treatment and/or for prevention44). For example, 
there is a high risk of respiratory failure after thoraco-
abdominal surgery45), lung resection46), and other 
surgeries. Many types of interfaces, such as nasal 
masks, face masks, ful-face masks, and helmets, are 
sold commercialy and their usefulness has increased 
considerably.
　Invasive ventilation with unnecessary tracheal 
intubation should be reduced by using NPPV. 
Recently, a trial to classify acute heart failure into five 
categories was proposed based on the onset 
mechanism and circulatory conditions47).
 (I) Crisis of heart failure with blood pressure of > 
140 mmHg and difuse edema in the lungs during 
the shrinkage period.
(II) Heart failure with blood pressure from 140 to100 
mmHg and slight edema in the lungs.
(III) Blood pressure of < 100 mmHg with heart 
dysfunction and/or cardiac shock.
(IV) Acute coronary syndrome.
 (V) Right heart failure.
　Identifying those patients who require respiratory 
management is relatively easy, particularly for those 
with heart failure and with blood pressure of > 100 
mmHg (I) (II) and those with acute coronary 
syndrome (IV). NPPV should be selected as a first 
choice for these conditions.
(9) HFNC
　Finaly, we discuss a recent topic: the oxygen 
therapy for respiratory failure that is efectively less 
than that of mild to moderate ARDS. Oxygen therapy 
is usualy provided by using an oxygen mask or a 
nasal cannula. High Flow Nasal Cannula (HFNC) 
oxygen therapy is a method for delivering a high 
volume of gas from a nasal cannula to the nasal 
cavities48), 49).
　Nasal cavity mucous membranes are occasionaly 
damaged due to dry gas, and when oxygen is delivered 
at > 3L/m through a normal nose cannula, nasal 
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bleeding may be induced. In contrast, HFNC does not 
dry the respiratory tract and does not slow ciliary 
movement, as the high volume of gas is suficiently 
warmed and humidified. Therefore, epistaxis usualy 
does not occur. Regarding clinical evidence, when it 
works wel, HFNC therapy improves oxygenation, 
decreases the respiratory rate within one hour, and 
releaves dyspnea for a mild to moderate respiratory 
failure patient48). As for its physiological efect, this 
treatment produces a slight PEEP to the upper 
respiratory tract (3-8 cmH2O with 30L/min). It has 
been estimated that a slight PEEP wil increase 
FRC49) as wil a smal PEEP. It improves the gas 
conductivity of the peripheral airway, and it also 
washes away the gas in the airway of dead space.
　It has been noted that patients with HFNC look 
better than with other treatments, due to the simple 
treatment with a nasal canula. However, it should be 
cautioned that hypoxia could occur if the cannula 
comes out of the nostrils. Level 2C evidence of HFNC 
has been provided for respiratory failure30) with sepsis 
in infants. Clinicaly, HFNC is thought to provide 
respiratory management between that of oxygen 
therapy and NPPV.
Summary
　We have described recent respiratory management 
strategies, including evidence based on the Berlin 
Definition used for ARDS. We hope that this wil 
contribute to everyday clinical procedures used for 
treating respiratory failure patients.
References
 1 . Vilar J, Sulemanji D, Kacmarek RM: The acute 
respiratory distress syndrome: incidence and mortal-
ity. Has it changed ? Curr Opin Crit Care 2014; 20: 3-9
 2 . Wang CY, Calfee CS, Paul DW, Janz DR, May AK, 
Zhuo H, et al.: One-year mortality and predictors 
death among hospital survivors of acute respiratory 
distress syndrome. Intensive Care Med. 2014; 17: DOI 
10.1007/s00134-013-3186-3
 3 . Ashbaugh DG, Bigelow DB, Petty TL, Levine BE: 
Acute respiratory distress in adults. Lancet 1967; 2: 
319-323
 4 . Bernard GR, Artigas A, Brigham KL, Carlet J, Falke 
K, Hudson L. et al.: The American-European 
Consensus Conference on ARDS. Definitions, mecha-
nisms, relevant outcomes, and clinical trial coordina-
tion. Am J Respir Crit Care Med 1994; 149(3 Pt 1): 
818-824
 5 . The Acute Respiratory Distress Syndrome Net-
work. Ventilation with lower Vt as compared with 
traditional Vt for acute lung injury and the acute 
respiratory distress syndrome. N Engl J Med 2000; 
342: 1301-1308
 6 . Luhr OR, Antonsen K, Karlsson M, Aardal S, 
Thorsteinsson A, Frostel CG, et al.: Incidence and 
mortality after acute respiratory failure and acute 
respiratory distress syndrome in Sweden, Denmark, 
and Iceland. The ARF Study Group. Am J Respir Crit 
Care Med 1999; 159(6): 1849-1861
 7 . Ferguson ND, Fan E, Camporota L, Antoneli M, 
Anzueto A, Beale R, et al.: The Berlin definition of 
ARDS: an expanded rationale, justification, and 
supplementary material. Intensive Care Med 2012; 38 
(10): 1731-1732
 8 . ARDS Definition Task Force, Acute respiratory 
distress syndrome: the Berlin Definition. JAMA 2012 
Jun 20; 307(23): 2526-2533
 9 . Ware LB, Matthay MA.: The acute respiratory 
distress syndrome. N Engl J Med 2000; 342: 1334-1349
10. Thile AW, Esteban A, Fernández-Segoviano P, 
Rodriguez JM, Aramburu JA, Peñuelas O, et al.: 
Comparison of the Berlin Definition for Acute 
Respiratory Distress Syndrome with Autopsy. Am J 
Respir Crit Care Med 2013; 187: 761-767
11. Perel A.: Extravascular lung water and the 
pulmonary vascular permeability index may improve 
the definition of ARDS. Crit Care 2013; 17(1): 108
12. Tobin MJ.: Advances in Mechanical Ventilation. N 
Engl J Med 2001; 344: 1986-1996
13. NHLBI Acute Respiratory Distress Syndrome 
Clinical Trials Network. Lower tidal volume ventila-
tion and plasma cytokine markers of inflammation in 
patients with acute lung injury. Crit Care Med 2005; 
33(1): 1-6
14. Petrucci N, Iacoveli W.: Ventilation with smaler 
tidal volumes: a quantitative systematic review of 
randomized controled trials. Anesth Analg 2004; 
99(1): 193-200
15. Slutsky AS, Hudson LD.: PEEP or no PEEP-lung 
recruitment may be the solution. N Engl J Med 2006 
Apr 27; 354(17): 1839-1841
Kawamae, Oda, Okada, Akimoto, Onodera, Suzuki, Nakane
－ 74 －
16. Meade MO, Cook DJ, Guyatt GH, Lung Open 
Ventilation Study Investigators: Ventilation strategy 
using low tidal volumes, recruitment maneuvers, and 
high positive end-expiratory pressure for acute lung 
injury and acute respiratory distress syndrome: a 
randomized controled trial. JAMA 2008 Feb 13; 
299(6): 637-645
17. Gattinoni L, Caironi P.: Refining Ventilatory 
Treatment  for  Acute  Lung  Injury  and  Acute 
Respiratory Distress Syndrome JAMA. 2008; 299(6): 
691-693
18. Briel M, Meade M, Mercat A,  Brower RG, Talmor 
D, Walter SD, et al.: Higher vs lower positive end-
expiratory pressure in patients with acute lung injury 
and acute respiratory distress syndrome: systematic 
review and meta-analysis. JAMA 2010 Mar 3; 303(9): 
865-873
19. Hodgson C, Keating JL, Holand AE, Davies AR, 
Smirneos  L,  Bradley  SJ,  et  al.:  Recruitment 
manoeuvres for adults with acute lung injury 
receiving mechanical ventilation. Cochrane Database 
Syst Rev 2009 Apr 15;(2): CD006667
20. Gattinoni L, Tognoni G, Pesenti A, Taccone P, 
Mascheroni D, Labarta V, et al.: Effect of prone 
positioning on the survival of patients with acute 
respiratory failure. N Engl J Med 2001; 345(8): 568-
573
21. Abrog F, Quanes-Besbes L, Elatorous S, Brochard L. 
et al.: The effect of prone positioning in acute 
respiratory distress syndrome or acute lung injury: a 
meta- analysis. Areas of uncertainty and recommenda-
tions for research. Intensive Care Med 2008; 34: 1002-
1011
22. Abroug F, Ouanes-Besbes L, Dachraoui F, Ouanes I, 
Brochard L.: An updated study-level meta-analysis of 
randomised controled trials on proning in ARDS and 
acute lung injury. Critical Care 2011, 15:R6
23. Gattinoni L, Taccone P, Carlesso E, Marini JJ.: 
Prone position in acute respiratory distress syndrome. 
Rationale, indications, and limits. Am J Respir Crit 
Care Med 2013; 188: 1286-1293
24. Beitler JR, Shaefi S, Montesi SB, Devlin A, Loring 
SH, Talmor D, et al.: Prone positioning reduces 
mortality from acute respiratory distress syndrome in 
the low tidal volume era: a meta-analysis. Intensive 
Care Med 2014; 17; 10.1007/s00134-013-3194-3
25. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, 
Perrin G, Loundou A, et al.: Neuromuscular Blockers 
in Early Acute Respiratory Distress Syndrome. N Engl 
J Med 2010; 363(12): 1107-1116
26. Neto AS, Pereira VG, Espósito DC, Damasceno MC, 
Schultz MJ.: Neuromuscular blocking agents in 
patients with acute respiratory distress syndrome: a 
summary  of  the  current  evidence  from  three 
randomized controled trials. Ann Intensive Care 
2012. 26; 2(1): 33
27. Guldner A, Pelosi P, Gama AM.: Spontaneous 
breathing in mild and moderate versus severe acute 
respiratory distress syndrome. Curr Opin Crit Care 
2014; 20: 76-79
28. Brochard L.: Measurement of esophageal pressure 
at bedside: pros and cons. Curr Opin Crit Care 2014; 
20: 39-46
29. Burns KE, Adhikari NK, Slutsky AS, Guyatt GH, 
Vilar J, Zhang H, et al.: Pressure and volume limited 
ventilation for the ventilatory management of patients 
with acute lung injury: a systematic review and meta-
analysis. PLoS One 2011 Jan 28; 6(1): e14623
30. Delinger RP, Levy MM, Rhodes A, Annane D, 
Gerlach H, Opal SM, et al.: Surviving sepsis campaign: 
international guidelines for management of severe 
sepsis and septic shock, 2012. Intensive Care Med 
2013; 39(2): 165-228
31. Sud S, Sud M, Friedrich JO, Meade MO, Ferguson 
ND, Wunsch H, et al.: High frequency oscilation in 
patients with acute lung injury and acute respiratory 
distress syndrome (ARDS): systematic review and 
meta-analysis. BMJ 2010 May 18; 340: c2327
32. Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand 
L, Austin P, et al.: High-frequency oscilation in early 
acute respiratory distress syndrome. N Engl J Med 
2013; 368(9): 795-805
33. Young D, Lamb SE, Shah S, MacKenzie I, 
Tunnicliffe W, Lal R, et al.: High-frequency oscilation 
for acute respiratory distress syndrome. N Engl Med 
2013; 368(9): 806-813
34. González M, Arroliga AC, Frutos-Vivar F, Raymon-
dos K, Esteban A, Putensen C, et al.: Airway pressure 
release ventilation versus assist-control ventilation: a 
comparative propensity score and international cohort 
study. Intensive Care Med 2010; 36: 817-827
35. Afshari A, Brok J, Møler AM, Wetterslev J.: Inhaled 
nitric oxide for acute respiratory distress syndrome 
and acute lung injury in adults and children: a 
systematic review with meta-analysis and trial 
sequential analysis. Anesth Analg 2011; 112(6): 1411-
1421
36. Takeda S, Kotani T, Nakagawa S, Ichiba S, Aokage 
Current respiratory management for ARDS
－ 75 －
T, Ochiai R, et al.: Extracorporeal membrane 
oxygenation for 2009 influenza A(H1N1) severe 
respiratory failure in Japan. J Anesth 2012; 26(5): 650-
657
37. Daniel B, Matthew B.: Extracorporeal Membrane 
Oxygenation for ARDS in Adults. N Engl J Med 2011; 
365: 1905-1914
38. Antoneli M, Conti G, Moro ML, Esquinas A, 
Gonzalez-Diaz G, Confalonieri M, et al.: Predictors of 
failure of noninvasive positive pressure ventilation in 
patients with acute hypoxemic respiratory failure: a 
multi center study. Intensive Care Med 2001; 27: 1718-
1728
39. Ferrer M, Esquinas A, Leon M. Gonzalez G, Alarcon 
A, Torres A.: Non-invasive ventilation in severe 
hypoxemic respiratory failure: a randomized clinical 
trial. Am J Respir Crit Care Med 2003; 168: 1438-1444
40. Vital FM, Saconato H, Ladeira MT. Sen A, Hawkes 
CA, Soares B, et al.: Non-invasive positive pressure 
ventilation (CPAP or bilevel NPPV) for cardiogenic 
pulmonary edema. Cochrane Database Syst Rev 2008 
Jul 16;(3): CD005351
41. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, et 
al.: Meta-analysis: Noninvasive ventilation in acute 
cardiogenic pulmonary edema. Ann Intern Med 2010 
May 4; 152(9): 590-600
42. Peter JV, Moran JL, Philips-Hughes J, Warn D, et 
al.: Noninvasive ventilation in acute respiratory 
failure meta-analysis updates. Crit Care Med 2002; 30: 
555-562
43. Antoneli M, Conti G, Bufi M, Costa MG, Lappa A, 
Rocco M, et al.: Noninvasive ventilation for treatment 
of acute respiratory failure in patients undergoing 
solid organ transplantation: A randomized trial. 
JAMA 2000; 283: 235-241
44. Squadrone V, Coha M, Cerutti E, Schelino MM, 
Biolino P, Occela P, et al.: Continuous positive airway 
pressure for treatment of postoperative hypoxemia. A 
randomized controled trial. JAMA 2005; 293: 589-595
45. Kindgen-Miles D, Müler E, Buhl R, Böhner H, 
Ritter D, Sandmann W, et al.: Nasal-continuous 
positive airway pressure reduces pulmonary morbidity 
and length of hospital stay folowing thoracoabdomi-
nal aortic surgery. Chest 2005; 128: 821-828
46. Auriant I, Jalot A, Hervé P, Cerrina J, Le Roy 
Ladurie F, et al.: Noninvasive ventilation reduces 
mortality in acute respiratory failure folowing lung 
resection. Am J Respir Crit Care Med 2001; 164: 1231-
1235
47. Mebazaa A, Gheorghiade M, Piña IL, et al.: 
Practical recommendations for prehospital and early 
in-hospital management of patients presenting with 
acute heart failure syndromes. Crit Care Med 2008; 
36(1 Suppl): S129-139
48. Sztrymf B, Messika J, Mayot T, Harjola VP, 
Holenberg SM, Folath F, et al.: Impact of high-flow 
nasal cannula oxygen therapy on intensive care unit 
patients with acute respiratory failure: a prospective 
observational study. J Crit Care 2012 Jun; 27(3): 324. 
e9-13
49. Corley A, Caruana LR, Barnett AG, Tronstad O, 
Fraser JF.: Oxygen delivery through high-flow nasal 
cannulae increase end-expiratory lung volume and 
reduce respiratory rate in post-cardiac surgical 










































































a                           　　　　            b
図２．a）回盲部から55cmで、小腸が嵌頓して内ヘルニアになっていた。
　　　b）直径約２cmの左子宮広間膜裂孔（矢印）を確認して閉鎖した。
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A case of internal herniation through a broad ligament defect
of uterus diagnosed preoperatively by computed tomography
Kenichi Shibata*, Yuji Onodera**, Motohisa Hagiwara**, Masahiro Chin**,
Eiji Hashizume**, Akira Suzuki**, Wataru Kimura*
*First Depertment of Surgery, Yamagata University Faculty of Medicine
**Department of Surgery, Nihonkai General Hospital
　We report a case of internal herniation through a broad ligament defect of uterus diagnosed 
preoperatively by computed tomography (CT). A 59-year-old woman presenting with lower abdominal 
pain was admitted to our hospital. Abdominopelvic CT revealed a dilated smal intestinal loop to the left 
of the uterus and the displacement of the uterus and rectum toward the right side. We diagnosed the 
patient with internal herniation through a broad ligament defect of uterus and performed emergency 
surgery. A smal intestinal segment was incarcerated in the left uterine broad ligament. Therefore, we 
released the herniation then detected a defect of the uterine broad ligament, which was about 2 cm in 
diameter. We sutured the defect and partialy resected the smal intestine. In this case, CT was useful to 
diagnose this condition. The characteristic CT appearances of this disease are localized and dilated 
intestinal loops in the pelvic cavity, and intestinal loops compressing the rectum and the uterus. 
Therefore, we recommend that this condition be kept in mind in case of female patients presenting with 
ileus without prior laparotomy.
Key words : broad ligament hernia, smal intestine ileus
ABSTRACT
Depression accompanied by multiple somatic delusions
－ 81 －
Introduction
　More than half of patients with delusional disorder 
somatic type (DDST), which is characterized by 
somatic delusions such as infestation delusion and 
delusion of body odor, develop secondary depression1). 
In contrast, only about 15% of cases of major 
depressive disorder (MDD) are accompanied by 
psychotic features, typicaly as delusions of guilt and 
hypochondriacal delusions2). We report herein the case 
of a patient with MDD accompanied by multiple 
somatic delusions.
Case Report
　The patient was a 55-year-old woman. She 
consented to this report of her clinical course. Her 
social and occupational histories were normal. Figure 
1 shows the clinical course. In October 2009, she 
developed depressive mood, diminished interest and 
pleasure, loss of energy, dificulty concentrating, 
insomnia, and feelings of worthlessness and guilt. 
These depressive symptoms gradualy progressed. 
From February 2010, she felt that “some liquid” was 
weling out from the skin of her palms, soles and face. 
She felt that her skin was slippery, sticky and 
becoming thinner. Independent of this feeling, she 
also felt that she was emitting a foul odor from her 
body. She demanded that her family members “Burn 
me to death, because I am emitting a bad smel”. 
Finaly, she tried to drown herself in the river, and 
was admitted to a psychiatric hospital. Trazodone at 
100 mg/day and olanzapine at 5 mg/day for three 
weeks proved inefective, and she was not eating at 
al. She was therefore referred to our ward in March 
2010.
　On examination, she had severe depressive 
symptoms and multiple somatic delusions, but no 
other psychiatric symptoms. No halucinations, 
disorganized  speech,  disorganized  or  catatonic 
behavior, afective flattening, or alogia were observed. 
Blood testing and magnetic resonance imaging 
showed no abnormalities. MDD with psychotic 
Yamagata Med J 2014；32(2)：81-83
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　About 15% of cases of major depressive disorder (MDD) are accompanied by psychotic features, 
typicaly as delusions of guilt and hypochondriacal delusions. We report the case of a 55-year-old woman 
with MDD accompanied by delusions of infestation and body odor, which are characteristic of delusional 
disorder somatic type (DDST). She developed a major depressive episode that gradualy deteriorated. 
Four months later, she felt that “some liquid” was weling out from skin of her palms, soles and face, 
and also that she was emitting a foul odor from her body. Treatment with paroxetine at 40 mg/day and 
olanzapine at 5 mg/day resolved somatic delusions, but some depressive symptoms remained. After 
addition of mirtazapine 30 mg/day, depressive symptoms were completely resolved. The present report 
definitively shows that MDD can accompany multiple somatic delusions typicaly observed in DDST.




features was diagnosed in accordance with the 
Statistical Manual of Mental Disorders (DSM-IV-
TR)3). Trazodone was switched to paroxetine at 10 
mg/day, while olanzapine was continued. After 4 
weeks, the dose of paroxetine was increased to 40 
mg/day. Depressive symptoms and somatic delusions 
then started improving gradualy. By day 50, somatic 
delusions had resolved completely, and she stated that 
“My depressive symptoms have recovered about 
70%”. On day 98, mirtazapine at 15 mg/day was 
added to treat residual loss of energy, and the dose 
was increased to 30 mg/day after 4 weeks. By day 130, 
depressive symptoms had resolved completely.
Discussion
　The patient in the present case was convinced that 
liquid was weling out from her skin, which was 
considered as a delusion of infestation or emanation. 
She also had a firm belief that she was emitting a foul 
odor from her body; that is, delusion of body odor. 
These somatic delusions were preceded by depressive 
symptoms, and resolved before the disappearance of 
the depressive symptoms, and so existed only during 
the major depressive episode. The present report 
therefore definitively shows that MDD can accom-
pany somatic delusions typicaly observed in DDST, 
such as infestation delusion and delusion of body odor. 
In the literature, another case report has described 
MDD accompanied by a somatic delusion4). However, 
the somatic delusion in that case was confined to a 
single theme, with the patient believing that his 
hands and feet were shorter than usual. This report is 
thus the first to describe MDD accompanying 
multiple somatic delusions.
　The mechanisms underlying this phenomenon 
remain unclear, but one possibility is that the somatic 
delusions developed as an amalgam of feelings of 
guilt2) and altered bodily sensations5) during a major 
depressive episode. That is, feelings of guilt may lead 
to misinterpretation of the gestures and comments of 
others as signs of criticism directed to the self, while 
unusual bodily sensations may lead to harboring an 
idea that something is wrong with one’s body. A 
patient with both feelings of guilt and unusual bodily 
sensations may thus come to believe that they are 
annoying others by emanating something unpleasant 
from their body.
　In the present case, a switch from trazodone to 
paroxetine was made due to the inefectiveness of 
trazodone and the possible antipsychotic efect of 
paroxetine6). The addition of mirtazapine to paroxet-
ine was because of the reported eficacy of this 
combination therapy7). The present report suggests 
　Figure 1. Clinical course of the present case.
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the usefulness of the combination of paroxetine, 
mirtazapine and olanzapine for MDD accompanied by 
multiple somatic delusions, but this should be 
confirmed in further studies.
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The HECT-Type Ubiquitin E3 Ligase ITCH Interacts with Thioredoxin-
Interacting Protein and Ameliorates Reactive Oxygen Species-Induced 
Cardiotoxicity
○Yoichiro Otaki*, MD, Hiroki Takahashi*, MD, PhD, Tetsu 
Watanabe*, MD, PhD, Akira Funayama*, MD, PhD, Yuki Honda*, 
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Hasegawa*, MD, PhD, Shintaro Honda*, MD, PhD, Takanori 
Arimoto*, MD, PhD, Tetsuro Shishido*, MD, PhD, Takehiko 
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Background: HECT-Type ubiquitin E3 ligase ITCH is an enzyme 
which plays a pivotal role in posttranslational modification by ubiquitin 
proteasomal protein degradation. Thioredoxin-interacting protein 
(TXNIP) is a negative regulator of thioredoxin system, which is an 
endogenous reactive oxygen species (ROS) scavenger. In the present 
study, we focused functional role of ubiquitin E3 ligase ITCH and its 
interaction with TXNIP to elucidate the mechanism of ROS-induced 
cardiotoxicity, such as doxorubicin (Dox) and hydrogen peroxide (H2O2).
Methods and Results: We confirmed protein interaction between 
TXNIP  and  ITCH  by  immunoprecipitation  in  cardiomyocyte. 
Overexpression of ITCH increased proteasomal TXNIP degradation and 
augmented thioredoxin activity, which may inhibit ROS-induced 
cardiomyocyte apoptosis in ROS-induced cardiotoxicity. Conversely, 
knockdown of ITCH by siRNA inhibited TXNIP degradation and 
demonstrated a subsequent increase in cardiomyocyte apoptosis. Next, 
we generated cardiac-specific overexpression of ITCH transgenic mouse 
(ITCH-Tg mice). The myocardium of ITCH-Tg mice had significantly 
lower expression levels of TXNIP than wild type littermates. ITCH-Tg 
mice restored an apoptosis in cardiac cels and cardiac dysfunction 
compared with wild type littermates after Dox injection. Kaplan-Meier 
analysis revealed that ITCH-Tg mice had higher survival rate than wild 
type littermates after Dox injection.
Conclusion: We demonstrated for the first time that ITCH targets 
TXNIP for ubiquitin-proteasome degradation in cardiomyocyte and 










































































































































NOD（Nucleotide oligomerization domain）様受容体（NOD-like receptor: 
NLR）などのパターン認識受容体が関与する。無菌性弛緩人工関節の病態
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